Design for the patient experience
ICON is empowering patients, encouraging compliance, and easing the burden of participating in trials through its patient centred services, backed by extensive research on behavioural decision-making and information technology.
Insights and guidance to ensure patient safety and global compliance at all stages of clinical research through the science of pharmacovigilance.
In this whitepaper we introduce the basic principles of sound longitudinal qualitative research and offer advice for sponsors considering such an approach as a way of insuring that their development efforts are patient centric.Read the whitepaper
Paving the way for diversity and inclusion in clinical trials: establishing a platform for improvement
This whitepaper examines the barriers to accessing under-represented subgroups, the regulatory landscape and how organisations are addressing this issue.Read the whitepaper
Currently, 6,000 to 8,000 rare diseases have been identified worldwide, and an estimated 250 to 280 new ones are discovered annually. ICON analysed data on the use of patient-reported outcomes measures (PROMs) in orphan drug labeling claims and performed an extensive literature review on the use of PROMs in all phases of clinical research.Read the whitepaper
There is no substitute for speaking directly with patients. Regulatory agencies, HTAs and researchers agree and are encouraging qualitative research to enrich quantitative data in RCTs. Read our whitepaper for insights on effectively integrating qualitative interviews into your protocol.Read the whitepaper
In the US, payers have historically focused on efficacy and safety endpoints as well as cost, with very little attention given to patient reported outcomes (PROs). With the increase in patient centricity, we surveyed US payers to learn if they were changing their approach.
Read the whitepaper
In early 2020, ICON invited distinguished speakers - a patient advocate, a clinical investigator and a pharmaceutical executive - to participate in a panel discussion, chaired by ICON's Dr. Nuala Murphy. The panellists discussed the dynamics of patient centricity in clinical research from their diverse stakeholder positions. This report is a summary of their lively and informative discussion.Read the report
The FDA encouraged sponsors to explore alternative methods for patient safety assessments, in the recent guidance on clinical trials during COVID-19. Decentralised and hybrid trials have been prevalent for years, but sponsors have struggled to execute effectively. Explore the perceived barriers and how you can make these models a feasible option for the future.Read the whitepaper
ICON conducted a survey through its Global Site Network to get the patient view on decentralised trials and find out whether bringing the trial to the patient could really make a difference in accessing more patients. We explored perceptions and preferences around what makes it easier for patients to participate in clinical trials and to determine whether industry perception of patient burden was the reality.Learn More
In our latest whitepaper, we follow a theoretical patient through the entire clinical trial journey – from initial contact for an early study through transition to treatment with an approved product. At each stage, we explore how IoMT can increase clinical development programme efficiency by reducing the burden on patients, caregivers, pharma companies and medical device and diagnostic manufacturers.Read the whitepaper
Many patients with serious diseases cannot wait for an investigational product to move from the lab to the pharmacy shelf. Managed Access Programs are one solution for early access to investigational products. Read our whitepaper to prepare for the clinical and operational complexities.
While pharma has historically focused their medical communications strategies and scientific data dissemination plans to physicians and payers, they have done little to explore the needs of nurses, who also play a central role in patient care. We surveyed 100+ oncology nurses to understand their medical communication needs and preferences and to identify any gaps.
Read our whitepaper for insights on how to design and execute a medical communications program that speaks directly to nurses for greater patient access and engagement across therapeutic areas.
Thanks to the web, community groups on social media (such as patient-advocacy groups) and real-time access to physiological data from wearables and smartphone apps, patients can be better informed than they ever have been.
ICON is working with the International Consortium for Health Outcomes Measurement (ICHOM) to develop The Global Outcomes Benchmarking (GLOBE) program. Rather than focusing on clinical indicators, ICHOM shifts the focus to outcomes that patients care about, including functional improvements and the capacity to live productive lives.
ICON Insights: mHealth devices allow for better treatments and clinical outcomes - Continuous monitoring of patients enables continuous treatment adjustments and alerts clinicians when emergencies arise - resulting in better, more personalised treatment and improved clinical outcomes, with fewer clinic visits and greater independence for patients.
The long journey towards patient centricity - A look at the regulatory efforts implemented in the last 30 years to include the patients’ perspective into drug development.
Patient Centric Monitoring is ICON’s methodology for the design and execution of an adaptive risk based monitoring strategy guided by risk assessment using ICONIK analysis. Risk based monitoring in clinical trials is a monitoring approach where activities, resources and technologies are adapted to the risks in the study. Patient Centric Monitoring further focuses on the probability of errors that matter in decision making for patients.
Today, fewer and fewer patients passively accept physicians’ advice. Patients are increasingly active, informed consumers entering clinics armed with research and opinions about their healthcare options. They desire data on similar patients while calculating the benefits and risks of their choices. To the patient–consumer, "precision medicine" represents the ideal standard of care: the individualised, evidence-based treatment that provides the best opportunity for a positive outcome. Read our three-part series exploring the patient-consumer:
Part One: From biomarkers to biosensors
If you would like to receive our Patient Centricity email updates, including the latest on companion diagnostics, drug safety, optimising late phase studies, as well as patient reported outcomes and site and patient recruitment, visit our preference centre.Receive Patient Centricity email updates
Registries are economical and flexible, and ideal for collecting data from a wide range of patients and sites, generating the real world evidence regulators and payers require to demonstrate effectiveness and safety, and to support label and coverage extensions. But this flexibility also creates risk. To generate useable, uniform data, registries must be carefully designed and administered. Consider these seven factors as you design and launch a successful registry.